• Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) provided an enrollment update for the ongoing Phase 2 trial of ELX-02 to treat cystic fibrosis (CF) in patients with at least one G542X allele.

• Based on enrollment to date, Eloxx expects to present data from the first four treatment arms in Q4 of 2021.

• As of the end of June 2021, Eloxx has enrolled a sufficient number of patients to assess the biological activity of ELX-02.

• ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene.

• Recently, a fifth treatment arm was added to the program to evaluate the safety of ELX-02 in combination with Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) Kalydeco (ivacaftor), an FDA-approved CFTR potentiator for cystic fibrosis in patients with at least one mutation in their CF gene amenable to ivacaftor.

• The Cystic Fibrosis Foundation partially funds the program.

• The U.S. Food and Drug Administration has granted orphan drug designation for ELX-02 for the treatment of CF.

• Price Action: ELOX shares are up 2.6% at $1.98 during the premarket session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Ideaya Biosciences Launches Equity Offering Of M

• OncoSec Stock Jumps On Anti-Cancer Gene Therapy Trial Collaboration With Merck In Melanoma

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.